212Pb-PSMA / Orano - LARVOL DELTA

Radiochemistry and Comparative In Vitro Evaluation of PSMA-617 Labeled with 212Pb, 225Ac, and 177Lu. (SNMMI 2026) - "212Pb-PSMA-617 showed similar or better in vitro uptake compared to 177Lu-PSMA-617 in PSMA-positive cell lines. While 225Ac-PSMA-617 also showed selective and specific uptake in the two PSMA-positive cell lines, the uptake levels were substantially lower, likely due to the low molar activities achievable for 225Ac-PSMA-617 compared to 212Pb-PSMA-617 or 177Lu-PSMA-617."

Preclinical • Genito-urinary Cancer • Prostate Cancer • Solid Tumor

Radiochemistry and Comparative In Vitro Evaluation of PSMA-617 Labeled with 212Pb, 225Ac, and 177Lu. (SNMMI 2026) - "212Pb-PSMA-617 showed similar or better in vitro uptake compared to 177Lu-PSMA-617 in PSMA-positive cell lines. While 225Ac-PSMA-617 also showed selective and specific uptake in the two PSMA-positive cell lines, the uptake levels were substantially lower, likely due to the low molar activities achievable for 225Ac-PSMA-617 compared to 212Pb-PSMA-617 or 177Lu-PSMA-617."

Preclinical • Genito-urinary Cancer • Prostate Cancer • Solid Tumor

Mechanistic insights into the anti-tumor activity of ²¹²Pb-PSMA radioligand therapy (AACR 2026) - P1/2 | "Multiomics analyses highlighted the involvement of multiple mechanisms of action in the efficacy of 212Pb-ADVC001 which collectively resulted in effective cancer cell death. Mechanistic studies furthered the understanding of PC radiobiology and cellular responses to beta- and alpha-based RLT with the identification of a cell cycle arrest in PC specifically induced by 212Pb-PSMA."

Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Uncovering the mechanisms of action of 177Lu- and 212Pb- based PSMA radioligand therapies (AACR 2025) - "Introduction: 177Lu-PSMA-617 is the first FDA-approved targeted radioligand therapy (RLT), and in clinical trials, significantly prolonged survival and improved quality of life in patients with metastatic castration resistant prostate cancer (mCRPC). Comparison studies of 177Lu- and 212Pb-PSMA treatment on PC cells showed a higher efficacy of 212Pb-PSMA in vitro and in vivo supporting the clinical application of 212Pb-PSMA for mCRPC. Mechanistic studies furthered the understanding of PC radiobiology and cellular responses to beta- and alpha-RLT with the identification of a cell cycle arrest in PC specifically induced by 212Pb-PSMA."

Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Preclinical Evaluation of [212Pb]Pb-ADVC001: A Prostate-Specific Membrane Antigen-Targeted α-Therapy for Prostate Cancer. (PubMed, J Nucl Med) - "All treatments were well tolerated. The preclinical results support the clinical development of 212Pb-ADVC001 as a targeted α-therapy for the treatment of patients with PC."

Journal • Preclinical • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • FOLH1

First-in-Human Phase 0 Study of AB001, a Prostate-Specific Membrane Antigen-Targeted 212Pb Radioligand, in Patients with Metastatic Castration-Resistant Prostate Cancer. (PubMed, J Nucl Med) - "γ-camera imaging of AB001 was feasible, even at a microdose, and demonstrated metastatic targeting, albeit for only 1 lesion. The promising biodistribution and clearance encourage further clinical investigation."

Journal • P1 data • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • FOLH1